|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,170.00 JPY | -0.05% |
|
+1.73% | +3.68% |
| 06-26 | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| 06-24 | Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer | MT |
| Market Cap | 3,889B 24.02B 21.03B 19.41B 18.13B 34.13B 2,271B 34.9B 234B 90.19B 1,120B 90.2B 88.22B | P/E 2027 * |
11.2x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,813B 23.54B 20.61B 19.03B 17.77B 33.45B 2,226B 34.22B 229B 88.41B 1,098B 88.42B 86.48B | EV / Sales 2027 * |
1.7x | EV / Sales 2028 * | 1.68x |
| Free-Float |
98.88% | Yield 2027 * |
3.71% | Yield 2028 * | 3.83% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.51% | ||
| 1 week | +1.27% | ||
| Current month | -5.39% | ||
| 1 month | -0.64% | ||
| 3 months | -15.58% | ||
| 6 months | +3.20% | ||
| Current year | +3.20% |
| 1 week | 2,128 |  | 2,204 |
| 1 month | 2,041 | | 2,275 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.60% | +1.27% | +52.49% | +0.51% | 23.77B | |
| +1.81% | +11.60% | +58.61% | +164.79% | 1,077B | |
| +1.51% | +11.77% | +69.61% | +57.53% | 613B | |
| +0.38% | +10.56% | +39.49% | +90.88% | 448B | |
| +0.99% | +5.24% | +28.17% | +22.73% | 332B | |
| -0.14% | +7.58% | +39.85% | +27.25% | 293B | |
| -0.06% | +4.92% | +31.21% | +41.59% | 286B | |
| -0.96% | +4.98% | -28.02% | -40.96% | 215B | |
| +0.62% | +4.59% | +30.10% | +63.03% | 193B | |
| -1.21% | +1.17% | +14.15% | +66.20% | 159B | |
| Average | +0.09% | +6.71% | +33.57% | +49.36% | 363.98B | |
| Weighted average by Cap. | +0.64% | +9.05% | +43.07% | +81.00% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,249B 13.89B 12.16B 11.23B 10.48B 19.73B 1,313B 20.18B 135B 52.15B 648B 52.16B 51.01B | 2,079B 12.84B 11.24B 10.38B 9.69B 18.25B 1,214B 18.66B 125B 48.22B 599B 48.22B 47.16B |
| Net income | 346B 2.14B 1.87B 1.73B 1.61B 3.03B 202B 3.1B 20.77B 8.02B 99.61B 8.02B 7.84B | 327B 2.02B 1.77B 1.63B 1.53B 2.87B 191B 2.94B 19.66B 7.59B 94.28B 7.59B 7.42B |
| Net Debt | -76.78B -474M -415M -383M -358M -674M -44.83B -689M -4.61B -1.78B -22.12B -1.78B -1.74B | -391B -2.42B -2.12B -1.95B -1.82B -3.43B -228B -3.51B -23.5B -9.07B -113B -9.07B -8.87B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/06/26 | ¥2,170.00 | -0.05% | 2,649,500 |
| 29/06/26 | ¥2,171.00 | +1.21% | 10,716,900 |
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
| 25/06/26 | ¥2,147.00 | -0.58% | 4,672,000 |
| 24/06/26 | ¥2,159.50 | +1.24% | 5,998,200 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
